drugset / Trial / NCT06086704
Study of 18F-FFNP Breast PET/MRI
Phase 2
Recruiting
53 enrolled
University of Wisconsin, Madison
National Cancer Institute (NCI) · collab
Non-randomizedParallel-groupOpen-labelDiagnostic
Summary
This clinical trial will investigate an estrogen-regulated parameter as an early measure of endocrine therapy response: progesterone receptor (PR) protein with a progestin-based radioligand, 18F-fluorofuranylnorprogesterone (18F-FFNP). The overall purpose of this research is to test the efficacy of 18F-FFNP PET/MRI for predicting response to presurgical endocrine therapy and to determine the quantitative reliability of 18F-FFNP breast PET/MRI in patients with newly diagnosed PR+ primary breast cancer.
Timeline
- Start
- 2024-09-25
- Primary completion
- 2027-01
- Completion
- 2030-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 18F-fluorofuranylnorprogesterone | Diagnostic / imaging agent | 259 mbq | — |
| Subject | Anastrozole | Other / unclassified | 1 mg | Oral |
| Background | Gadopiclenol | Diagnostic / imaging agent | — | Intravenous |